NDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAXON (levobetaxolol hydrochloride) is an ophthalmic beta-blocker suspension approved in 2000 for the treatment of elevated intraocular pressure and glaucoma. It is administered as eye drops and works by reducing aqueous humor production in the eye.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30/100); brand team likely focused on transition planning and market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
78 enrolled
GlaucomaOcular Hypertension
Career Relevance
BETAXON currently has zero linked job openings and is in LOE-approaching phase, indicating minimal active hiring and career expansion. Roles on this product are primarily defensive, focused on managing market erosion and transition planning rather than growth.
Brand Manager
Worked on BETAXON at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.